<

Clinical application of urokinase

  Urokinase an enzyme protein isolated from the urine of a healthy person or obtained from human kidney tissue culture. Can be direct effects on endogenous fibrinolysis system, can into fibrinolytic enzyme catalytic cracking fibrinolytic enzyme, which can not only degradation of fibrin clot, also can degrade fibrinogen in blood, and clotting factor Ⅴ and blood coagulation factor Ⅷ etc, so as to play a role of thrombolysis. Urokinase has a quick and good effect on newly formed thrombus, and can also improve the activity of vascular ADP enzyme, inhibit adp-induced platelet aggregation, and prevent thrombosis. After intravenous infusion, the fibrinolytic activity in the patient's body was significantly increased, and the fibrinolytic activity returned to the original level after several hours of drug withdrawal.

  Urokinase can treat circulatory system diseases

  (1) clinical study of low dose urokinase combined with defibrase in the treatment of progressive cerebral infarction

  Progressive stroke is one of the most difficult to treat in cerebral infarction. At present, low-molecular-weight heparin is the first-line anticoagulant drug at home and abroad. In domestic studies, low-molecular-weight heparin calcium was used as the control in the treatment of progressive cerebral infarction by low-dose urokinase combined with defibrase. The results showed that the total effective rate of the treatment group was higher than that of the control group, and there was no case of cerebral hemorrhage. It is concluded that the combination of low-dose urokinase with defibrase can achieve stable thrombolytic, defibrinolytic and anticoagulant effects, and the treatment effect of progressive cerebral infarction is significant, which is worthy of clinical promotion.

  (2) high dose urokinase thrombolytic therapy for deep venous thrombosis of lower extremities after implantation of inferior vena cava filter

  Thrombolytic therapy with high dose urokinase for deep venous thrombosis of lower extremity after implantation of inferior vena cava filter. Urokinase (UK) dosage: 9 million U ~ 16 million U. Domestic research suggests 13 subjects, including: healing in 2 cases, 9 cases were markedly effective, effective in 2 cases, ineffective 0 cases, does not appear in the process of thrombolysis symptoms of pulmonary embolism and bleeding. Conclusion after inferior vena cava filter placement by limb high-dose intravenous urokinase thrombolysis treatment of lower extremity deep vein thrombosis is safe and effective.

  (3) application of urokinase with different doses in blocking of deep venous catheter in patients with malignant tumors

  Objective: to investigate the clinical effect of urokinase with different doses in dredging the blockage of deep venous catheter in malignant tumors. Methods 2 million U urokinase was added to 500ml normal saline (concentration of 4000U/ml) for dredging catheter treatment, and the control group was treated with urokinase with a concentration of 2000U/ml for dredging catheter treatment. Results the total recanalization rate of the observation group was 95.56%, significantly higher than the control group of 86.04%, the difference was statistically significant (P0.05). Conclusion 4000U/ml urokinase can effectively and safely dredge the blocked deep venous catheter in malignant tumors.

  (4) efficacy analysis of low-dose urokinase combined with low-molecular-weight heparin sodium in the treatment of elderly patients with acute coronary syndrome

  Studies have shown that low dose urokinase combined with low molecular weight heparin sodium in the treatment of elderly patients with acute coronary syndrome has a significant clinical effect, which is significantly better than the conventional treatment (beta blockers, calcium antagonists, nitrate esters, aspirin, clopidogrel, etc.).